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Abstract
Despite significant advances have been made in the recent years regarding organ-specific therapies, there is no
approved ‘disease-modifying’ antifibrotic drug for systemic sclerosis (SSc) available to date. Although non-selective
immunosuppressive agents are routinely used to treat patients with SSc, large well-controlled studies are lacking
for almost all immunosuppressive agents and further evidence is required for long-term beneficial effects of these
drugs. Considering these facts about immunosuppressive agents in SSc and also considering the high mortality of
SSc, other therapeutic strategies are urgently needed. Recently an important role of the 5-hydroxytryptamine (5-HT:
serotonin) pathway in fibrosis was reported. In this review, we discuss the role of 5-HT in fibrosis and therapeutic
potential of this molecule. Besides 5-HT, there are a number of promising targets that have been extensively
characterized in recent years. For many of these molecular targets, modifiers are readily available for clinical studies,
and often these modifiers are used already in clinical use for other diseases. Results from these studies will show,
in how far the promising preclinical results for novel antifibrotic strategies can be translated to clinical practice.
Introduction
Systemic sclerosis (SSc) is a multisystem connective tissue
disease that is characterized by fibrosis of the skin and
internal organs and also by widespread vasculopathy. Clin-
ical manifestations include thickening of the skin, Ray-
naud’s phenomenon, pulmonary arterial hypertension,
pulmonary fibrosis and involvement of other visceral
organs [1]. Histological hallmarks in the skin of early stage
of SSc are perivascular inflammatory infiltrates and micro-
vascular changes such as capillary dilatation with subse-
quent rarefaction. In later stage, this leads to tissue fibrosis
with an excessive accumulation of extracellular matrix
[2,3]. Tissue fibrosis disrupts the physiological tissue archi-
tecture and causes dysfunction of the affected organs.
O r g a nd y s f u n c t i o nc a nl e a dt oo r g a nf a i l u r ea n dc o n t r i -
butes profoundly to the increased mortality of SSc. Despite
intensive research, lack of evidence for the treatment of
SSc patients complicates the appropriate management of
SSc patients.
Although its etiology still remains unknown, knowledge
about the pathogenesis of SSc is rapidly increasing. Signifi-
cant progress has been achieved in the identification of
possible molecular targets for therapy in SSc. In this arti-
cle, we will summarize current therapeutic approaches
using immunosuppressive agents in SSc, discuss limita-
tions of such approaches and focus on novel molecular
targets for therapy to treat fibrotic manifestations by using
the 5-hydroxytryptamine (5-HT: serotonin) pathway as an
example.
Current therapy for SSc
Significant advances have been made in the recent years
regarding symptomatic organ-specific therapies [4]. How-
ever, there is no approved ‘disease-modifying’ drug for SSc
that modifies the fibrotic manifestations of the disease.
Non-selective immunosuppressive agents are routinely
used to treat patients with SSc. A recent report from the
German SSc registry showed that 41% patients received
corticosteroids and 36% received immunosuppressive
agents [5]. Despite their frequent use, there is only lim-
ited data on their efficacy in SSc and only few controlled
clinical studies have been performed for nonselective
immunosuppressive agents. The low prevalence of SSc,
various disease subsets and a highly variable course of
the disease are making it difficult to perform well-
designed clinical studies with a significant number of
patients [6]. Table 1 summarizes the main randomized
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Although there is clinical evidence that corticosteroid
treatment is effective for some clinical manifestations
that can occur in association with SSc such as inflamma-
tory arthritis and myositis, use of higher dose corticoster-
oids is not recommended in SSc except for certain
treatment-resistant and severe cases. The reason for this
recommendation is that several retrospective case-con-
trol studies revealed that corticosteroid doses with a pre-
dnisone equivalent of more than 15 mg/day increased
significantly the risk of developing scleroderma renal cri-
sis, which is a severe and life threatening disease manifes-
tation of SSc [7,8].
Large well-controlled studies are lacking for almost all
immunosuppressive agents that are used in SSc.
Table 1 Randomized controlled trials evaluating immunosuppressive/immunomodulatory drugs in patients with SSc.
Reference Treatment Number and main
inclusion criteria of SSc
patients
Study
duration
Clinical effect
Furst DE et al.
Arthritis
Rheum
1989;32:584
Chlorambucil p.o. 0.05-0.1 mg/kg/day versus placebo 65 SSc 3 years NS effect
O’Dell JR et al.
J Rheumatol
1989;32:584
Total lymphoid irradiation versus untreated control 6 SSc with internal organ
involvement
Follow-
up of 1-
4 years
NS effect
Casaes JA et
al.
Ann Rheum
Dis
1990;49:926
5-fluorouracil i.v. 4 × 12 mg/kg daily, followed by 4
× 6 mg/kg every two days and maintenance
therapy with 12.5 mg/kg weekly versus placebo
70 SSc (diffuse or limited
with visceral involvement)
6
months
Significant improvement in skin score,
Raynaud’s score and patient’s general
assesment scores
Sharada B et
al.
Rheumatol Int
1994;14:91
Dexamethasone i.v. 100 mg/month versus placebo 35 diffuse SSc 6
months
Significant improvement in skin score
Van den
Hoogen FH et
al.
Br J
Rheumatol
1996;35:364
Methotrexate i.m. 15 mg/week versus placebo 29 SSc with <3 years of
skin involvement or with
disease progression
24
weeks
Trend towards improvement in skin
score (p = 0.06 in comparison with
placebo)
Clements PJ
et al. Arthritis
Rheum
2001;44:1351
D-penicillamine p.o. high (750-1000 mg/d) versus
low (125 mg every second day) dose
134 early diffuse SSc 2 years NS effect
Pope JE et al.
Arthritis
Rheum
2001;44:1351
Methotrexate p.o. 15 mg/week versus placebo 71 early diffuse SSc 1 year Improvement in skin scores, borderline
significance
Tashkin DP et
al. N Eng J
Med
2006;354:2655
Cyclophosphamide p.o. 1-2 mg/kg/d versus placebo 154 SSc with early (<7
years duration) SSc,
symptomatic SLD and
alveolitis
1 year Significant improvement in lung
volumes, dyspnoea and some
measures of health related quality of
life.
Significant improvement in skin score
in diffuse SSc as a secondary outcome
measure
Hoyles Rk et
al.
Arthritis
Rheum
2006;54:3962
Cyclophosphamide 6 × i.v. 600 mg/m
2/month plus
oral predonisone 20 mg every second day followed
by azathioprine (p.o. 2.5 mg/kg/day) versus placebo
45 SSc with SLD 1 year Trend towards improvement of FVC (p
= 0.08), but low power
Nadashkevich
O et al.
Clin
Rheumatol
2006;25:205
Cyclophosphamide p.o. 2 mg/kg/d for 12 months,
then 1 mg/kg/d for another 6 months versus
asathioprine 2.5 mg/kg/d for 12 months and then 2
mg/kg/d for 18 months
60 early diffuse SSc (<12
months duration)
18
months
Significant improvement in skin score,
lung function tests and frequency of
attacks of Raynaud’s phenomenon
i.v. = intravenous, i.m. = intramuscular, p.o. = peroral, NS = not significant, SLD = scleroderma interstitial lung diseases, SSc = systemic sclerosis. This list is not
complete and is only a selection of potential molecules for targeted therapies. Modified from Distler O: Screloderma-modern aspects of pathogenesis, diagnosis
and therapy. UNI-MED 2009.
Iwamoto and Distler Fibrogenesis & Tissue Repair 2012, 5(Suppl 1):S19
http://www.fibrogenesis.com/content/5/S1/S19
Page 2 of 6However, few randomized RCTs for immunosuppressive
therapies are available. A beneficial effect on skin fibro-
sis was shown for methotrexate, 5-fluorouracyl, oral
cyclophosphamide and intravenous dexamethasone. This
effect was mainly seen in patients with diffuse SSc and
the effects were small. It is questionable whether these
effects are clinically meaningful. Beneficial effects on
internal organ involvement were only seen in patients
with scleroderma lung disease treated with oral cyclo-
phosphamide showing improved lung volumes and dys-
pnoea scores compared to placebo. Again, the observed
effects were small, and all effects seen with cyclopho-
sphamide treatment, except for sustained improvement
in patient-reported dyspnoea, waned within 12-18
months after stopping therapy [9]. Several other immu-
nosuppressive medications including mycophenolate
mofetil, anti-thymocyte globulin, azathioprine, cyclos-
porine, intravenous immunogloblins or combination of
cyclophosphamide with high dose corticosteroids have
shown some efficacy in small open-label, uncontrolled
studies or retrospective analyses, but well-performed
RCTs are not available.
In summary, small observational trials, case reports and
a limited number of RCTs suggested some efficacy of
immunosuppressive agents. Thus, an immunosuppressive
therapeutic approach may be considered in early inflam-
matory stages of diffuse SSc. However, further evidence is
required for long-term beneficial effects of these drugs. In
addition, the observed effects in clinical trials were often
small, which also reflects the experience in clinical prac-
tice. The potential toxicity of immunosuppressive treat-
ments also needs to be included in a risk/benefit analysis
and may limit long-term usage of these treatments in SSc.
Considering the high mortality of SSc secondary to fibrotic
manifestations, other therapeutic approach are urgently
needed for SSc.
Novel therapeutic target for fibrosis in SSc
Indeed, significant inflammatory infiltrates in the skin are
often limited to very early disease stages, and even in these
early disease stages meaningful infiltrates can only be
found in perivascular areas. There is also increasing evi-
dence that the molecular expression pattern in SSc skin is
extremely heterogeneous, and that only smaller subsets of
patients express increased levels of inflammatory mole-
cules [10]. Thus, unselective immunosuppressives might
be useful for smaller subsets of SSc patients, while the
large majority of patients might need different therapeutic
approaches. In this regard, mechanisms leading to the
increased synthesis of extracellular matrix proteins in
fibroblasts are of particular interest for targeted therapies.
Remarkable breakthrough findings have been obtained
regarding the identification of key molecules, key cellular
mechanisms, and key intracellular signaling cascades,
which mediate the perpetuation of fibrosis. These find-
ings have true translational implications, because the
modifiers of these key mediators and key mechanisms
are often in clinical use in other diseases such as cancer.
Among these key molecules, recent reports showed an
important role of the 5-hydroxytryptamine (5-HT: sero-
tonin) pathway in fibrosis [11]. Here, we focus on the ser-
otonin pathway as a novel target in the treatment of SSc
and summarize these recent results as an example for a
preclinical characterization of molecular targets in SSc.
Microvascular damage is one of the earliest features in
the pathogenesis of SSc leading to a progressive loss of
capillaries [12]. Microvascular injury precedes clinically
detectable tissue fibrosis in SSc. However, molecular
links between microvascular damage and the induction
of tissue fibrosis have not been established. One possible
link could be 5-HT, because the microvascular damage
with exposure of subendothelial connective tissue acti-
vates platelets and activated platelets release large
amounts of 5-HT. Based on these considerations and the
fact that 5-HT is elevated in the blood of SSc patients
[13-15], we hypothesized that 5-HT signaling might be
involved in the process of fibrosis in SSc [11].
First, we investigated, whether 5-HT is able to induce
the release of extracellular matrix proteins in SSc. Pri-
mary dermal fibroblasts from SSc patients and healthy
subjects, which were stimulated with 5-HT, increased the
mRNA of different extracellular matrix proteins such as
collagen type I alpha 1 (COL1A1), collagen type I alpha 2
(COL1A2) and fibronectin-1 in dose-dependent manner.
Similarly, the release of collagen protein was also
increased by 5-HT stimulation. Doses used for the stimu-
lations were in the range of those detected in biological
fluids.
There are seven 5-HT receptors, 5-HT1 to 5-HT7,
and the cellular effects of 5-HT are mediated by these
receptors. The identification of those receptors, which
play a crucial role in fibrosis, was necessary, because
receptor antagonists often show more efficacy and safety
than ligand antagonist. Thus, we next investigated,
which receptor specifically mediates the profibrotic
effects of 5-HT. We observed that three different 5-HT
receptors were expressed by dermal fibroblasts: 5-HT1B,
5-HT2A, and 5-HT2B. The mRNA levels of 5-HT2B were
up regulated in SSc fibroblasts as compared with healthy
controls (143 ± 17%), while 5-HT1B and 5-HT2A were
not different. Inhibition of 5-HT1 by selective chemical
inhibitors showed no reduction of the stimulatory effects
of 5-HT on extracellular matrix production in SSc fibro-
blasts. In contrast, inhibition of 5-HT2 decreased
mRNA levels of COL 1A1, COL 1A2 and fibronectin-1
and also decreased the release of collagen protein. Addi-
tional inhibition experiments using chemical inhibitors
as well as siRNA approaches revealed that this effect
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results suggested that 5-HT2B plays crucial role for the
synthesis of extracellular matrix proteins in dermal
fibroblasts.
Immunohistochemistry in fibrotic skin biopsies of SSc
patients and normal skin of healthy individuals backed up
these results. Expression of 5-HT2B was strongly increased
in fibrotic tissue as compared with unaffected tissue from
healthy controls. Double staining with the fibroblast-speci-
fic marker prolyl-4-hydroxylase-beta confirmed that
5-HT2B was mostly expressed by dermal fibroblasts, and
the large majority of fibroblasts stained positive for
5-HT2B in fibrotic tissue, but not in controls.
The profibrotic effects of 5-HT/5-HT2B could be
mediated via direct increase of collagen mRNA transcrip-
tion or indirectly via induction of a second mediator. We
suspected indirect mechanisms, because the effects of
5-HT in the COL1A2 reporter assay were delayed com-
pared to the effects of transforming growth factor-b
(TGF-b), which is a well known key player in the patho-
genesis of fibrosis [16]. Thus, we investigated, whether
TGF-b itself might be the second mediator of 5-HT sig-
nalling. Interestingly, 5-HT increased dose-dependently
mRNA levels of TGF-b1 in SSc fibroblasts. Furthermore,
5-HT induced in a time-dependent manner the nuclear
levels of phospho-Smad3, the typical intracellular media-
tor of TGF-b signalling. To evaluate whether TGF-b is
necessary for the profibrotic effect of 5-HT, we cultured
SSc fibroblasts with neutralizing antibodies against TGF-
b1. Inhibition of TGF-b1 completely abrogated the profi-
brotic effects of 5-HT on mRNA expression of COL1A1,
COL 1A2 and fibronectin-1.
Next, we aimed to demonstrate that these in vitro results
reflect in vivo situations by using the mouse model of
bleomycin-induced dermal fibrosis. Injection of bleomycin
potently stimulated the expression of 5-HT2B and induced
dermal fibrosis. The 5-HT2 inhibitors terguride and cypro-
heptadine as well as the selective 5-HT2B inhibitor SB
204741 [17-20] efficiently prevented bleomycine-induced
dermal thickening. Collagen content and myofibroblast
counts were also reduced dose-dependently by inhibition
of 5-HT2B. The antifibrotic effects of 5-HT2 inhibition
were further tested in a therapeutic approach using a
modification of the bleomycin model. Dermal thickening
decreased by 78 ± 4% in mice treated with terguride for
the last 3 weeks compared with placebo treated mice.
Finally, we used 5-HT2B -deficient mice to confirm the
role of 5-HT2B in experimental fibrosis. 5-HT2B
-/- mice
were almost completely protected from bleomycin-
induced dermal fibrosis, although no spontaneous histolo-
gical changes or differences in dermal thickness were
observed in untreated 5-HT2B
-/- mice.
There is no single animal model that completely cov-
ers the different aspects in the pathogenesis of SSc [21].
For example, in the bleomycin model, fibrosis is trig-
gered by intense inflammatory infiltrates in the skin. As
outlined above, inflammatory infiltrates are present in
early inflammatory stages of human SSc, but are not a
feature of later disease stages. Thus, for the identifica-
tion of potential molecular targets for therapy, testing in
at least one additional model is recommended [22]. We
therefore assessed the role of 5-HT2B in a less inflam-
mation-dependent mouse model of fibrosis, the tight
skin 1 (Tsk-1) model. As in human SSc and experimen-
tal bleomycin-induced fibrosis, 5-HT2B was overex-
pressed in skin sections of Tsk-1 mice. Hypodermal
thickening, collagen content, and differentiation of rest-
ing fibroblasts into myofibroblasts were significantly
reduced in Tsk-1 mice upon treatment with the 5-HT2B
inhibitor SB 204741. Similarly, Tsk-1 mice crossed with
5-HT2B
-/- mice showed reduced hypodermal thickening,
reduced collagen content, and decreased numbers of
myofibroblasts compared with TSk-1 mice crossed with
5-HT2B
+/+ mice.
To confirm the link between platelet activation and
increased 5-HT/5-HT2B signalling, we examined whether
inhibition of platelet activation reduces tissue levels of 5-
HT and prevents experimental fibrosis. Indeed, treatment
with the P2Y12 receptor inhibitor clopidogrel reduced the
content of 5-HT in fibrotic skin of bleomycin-challenged
mice by 58 ± 21%. In parallel, clopidogrel decreased der-
mal thickening by 61 ± 13% as compared with control
mice. This was also seen in Tsk-1 mice experiments, in
which treatment with clopidogrel reduced hypodermal
thickening by 51 ± 16%.
Tryptophan hydroxylase (TPH) 1 is the key enzyme
for the synthesis of 5-HT in platelets. Experiments with
TPH 1 deficient mice further underlined the important
role of platelet-derived 5-HT in experimental fibrosis.
Blood levels of 5-HT in TPH1
-/- mice were reduced to
5% compared with wild-type animals [23]. Dermal thick-
ening in bleomycin-challenged TPH1
-/- mice were
decreased by 61 ± 6% as compared with bleomycin-
challenged TPH1
+/+ mice. Similarly, collagen content
and myofibroblast counts were significantly reduced.
Conclusion
These data provide circumstantial evidence for 5-HT/5-
HT2B signalling as a potential therapeutic target in SSc.
They also provide a template for an extended pre-clinical
characterization of other potential therapeutic targets in
fibrotic diseases such as SSc. Indeed, there are a number
of promising targets that have been extensively character-
ized in recent years, and 5-HT/5-HT2B is just one exam-
ple among them. Table 2 gives an overview of potential
targets for therapy in SSc. Most interestingly, for many of
these molecular targets, modifiers are readily available for
clinical studies, and often these modifiers are used
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inhibitor terguride is approved in Japan for the treatment
of hyperprolactinemia and is currently tested in a proof
of concept trial in patients with SSc. This study has fin-
ished recruitment and is currently awaiting analysis. This
and similar studies will show, in how far the extended
preclinical characterization outlined above is able to pre-
dict clinical responses in human fibrotic diseases such as
SSc.
List of abbreviations used
SSc: Systemic sclerosis; RCTs: randomized controlled trials; 5-HT: 5-
hydroxytryptamine; COL1A1: collagen type I alpha 1; COL1A2: collagen type I
alpha 1; TGF-β:transforming; Tsk-1: tight skin 1; TPH: tryptophan hydroxylase.
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Table 2 Possible molecular targets for therapy in SSc
Target molecules Available drug name References
Tyrosine kinases Imatinib, Nilotinib, Dasatinib Iwamoto N et al.
Curr Rheumatol Rep.
2011;13:21
SRC kinases SU6656, Dasatinib Akhmetshina A et al.
FASEB J.
2008;22:2214
TGF-b inhibitors Several drugs Asano Y.
J Dermatol
2010;37:54
Histondeacetylase inhibitor Trichostatin, SAHA Huber LC et al.
Arthritis Rheum
2007;56:2755
DNA Methyltransferase inhibitors 5-AZA Wang Y et al.
Arthritis Rheum
2006;54:2271
Rho associated kinase Fasudil Akhmetshina A et al.
Arthritis Rheum
2008;58:2553
Cannabinoid receptor 2 (CB2) agonists Several drugs Akhmetshina A et al.
Arthritis Rheum.
2009;60:1129
PPAR g agonists None Wei J et al.
PloS One
2010;5:e13778
Adenosine A2A receptor blockers None Chan ES et al.
Arthritis Rheum.
2006;54:2632
IL-13 inhibitors None Lafyatis R et al.
Endocr Metab Immune Disord Targets
2006;6:395
Serotonin-Receptor-2B inhibitors Terguride Dees C et al.
J Exp Med.
2011; 208:961
CTGF inhibitor CTGF antibodies Wang Q et al.
Fibrogenesis Tissue Repair
2011;4:4
IL-6 receptor antagonist Tocilizmab Shima Y et al.
Rheumatology(oxford)
2010;49:2408
MicroRNA-29a None Maurer B et al.
Arthritis Rheum
2010;62:1733
Fos-Related Antigen-2 (AP-1 family) None Reich N et al.
Arthritis Rheum
2010;62:280
Maurer B et al.
Circulation.
2009;120:2367
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